CoChat
Sign Up
Cited by 61

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Nanomaterials: Breaking through the bottleneck of tumor immunotherapy

Kang, Yue, Li, Shenglong·2023·International Journal of Biological Macromolecules
DOI 10.1016/j.ijbiomac.2023.123159
Open this paper in CoChat — free account

Abstract

Immunotherapy exerts its excellent anti-tumor effects by stimulating and enhancing the immune response of the body, and has become another important class of anti-tumor therapy besides chemotherapy, targeted therapy and radiotherapy. Various types of immunotherapeutic drugs have gained their clinical values, but the in vivo delivery of drugs still faces many challenges, such as poor tumor permeability and low tumor cell uptake rate. In recent years, owing to highly targeting properties, better biocompatibility, and easy functionalization, nanomaterials have been widely applicated in tumor treatment, especially in tumor immunotherapy. Furthermore, nanomaterials have large drug loading capacity, strong tumor targeting and easy modification, which can effectively overcome the drawbacks of traditional immunotherapy. This paper reviews the progress of nanomaterial-based tumor immunotherapy in recent years and provides a theoretical basis for exploring new nanomaterial-based tumor immunotherapy strategies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijbiomac.2023.123159

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 143

  1. Yang, 2022, Biogenesis and regulatory roles of circular RNAs, Annu. Rev. Cell Dev. Biol., 38, 263, 10.1146/annurev-cellbio-120420-125117 · DOI
  2. Tang, 2022, Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy, Cancer Lett., 548, 10.1016/j.canlet.2022.215823 · DOI
  3. Chen, 2022, Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy, J. Control. Release, 348, 572, 10.1016/j.jconrel.2022.06.014 · DOI
  4. Zeng, 2022, Cell membrane coated-nanoparticles for cancer immunotherapy, Acta Pharm. Sin. B, 12, 3233, 10.1016/j.apsb.2022.02.023 · DOI · Paper page
  5. Chen, 2022, Colorectal cancer: metabolic interactions reshape the tumor microenvironment, Biochim. Biophys. Acta Rev. Cancer, 1877, 10.1016/j.bbcan.2022.188797 · DOI
  6. Paul, 2022, Targeting cancer stem cells in the tumor microenvironment: an emerging role of PARP inhibitors, Pharmacol. Res., 184, 10.1016/j.phrs.2022.106425 · DOI
  7. Yenyuwadee, 2022, Immune cellular components and signaling pathways in the tumor microenvironment, Semin. Cancer Biol., 86, 187, 10.1016/j.semcancer.2022.08.004 · DOI
  8. Li, 2022, Tumor microenvironment responsive nanocarriers for gene therapy, Chem. Commun. (Camb.), 58, 8754, 10.1039/D2CC02759C · DOI
  9. Li, 2022, Advances of bacteria-based delivery systems for modulating tumor microenvironment, Adv. Drug Deliv. Rev., 188, 10.1016/j.addr.2022.114444 · DOI
  10. Kwak, 2022, Tumor regionalization after surgery: roles of the tumor microenvironment and neutrophil extracellular traps, Exp. Mol. Med., 54, 720, 10.1038/s12276-022-00784-2 · DOI
  11. Peters, 2022, Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects, J. Immunother. Cancer, 10, 10.1136/jitc-2022-004863 · DOI
  12. Mansouri, 2022, Cancer genome and tumor microenvironment: reciprocal crosstalk shapes lung cancer plasticity, elife, 11, 10.7554/eLife.79895 · DOI
  13. Zhu, 2022, Posttranslational control of lipogenesis in the tumor microenvironment, J. Hematol. Oncol., 15, 120, 10.1186/s13045-022-01340-1 · DOI
  14. Martín-Otal, 2022, Impact of tumor microenvironment on adoptive T cell transfer activity, Int. Rev. Cell Mol. Biol., 370, 1, 10.1016/bs.ircmb.2022.03.002 · DOI
  15. Kwon, 2022, Potential pro-tumorigenic effect of bisphenol a in breast cancer via altering the tumor microenvironment, Cancers, 14, 3021, 10.3390/cancers14123021 · DOI
  16. Gao, 2022, Tumor microenvironment: lactic acid promotes tumor development, J. Immunol. Res., 2022, 10.1155/2022/3119375 · DOI
  17. Kuo, 2022, Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment, J. Biomed. Sci., 29, 56, 10.1186/s12929-022-00837-8 · DOI
  18. Xiang, 2022, Cancer-associated fibroblasts: vital suppressors of the immune response in the tumor microenvironment, Cytokine Growth Factor Rev., 67, 35, 10.1016/j.cytogfr.2022.07.006 · DOI
  19. Janssen, 2022, Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer, Cancer Treat. Rev., 109, 10.1016/j.ctrv.2022.102433 · DOI
  20. Paskeh, 2022, Emerging role of exosomes in cancer progression and tumor microenvironment remodeling, J. Hematol. Oncol., 15, 83, 10.1186/s13045-022-01305-4 · DOI
  21. Fujiwara, 2022, Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy, Cancer Treat. Rev., 110, 10.1016/j.ctrv.2022.102461 · DOI
  22. Wang, 2022, Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy, J. Hematol. Oncol., 15, 118, 10.1186/s13045-022-01335-y · DOI
  23. Gao, 2022, Tumor endothelial cell-derived extracellular vesicles contribute to tumor microenvironment remodeling, Cell Commun. Signal., 20, 97, 10.1186/s12964-022-00904-5 · DOI
  24. Grisaru-Tal, 2022, Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy, Nat. Immunol., 23, 1309, 10.1038/s41590-022-01291-2 · DOI
  25. Lund, 2022, Immune potential untapped: leveraging the lymphatic system for cancer immunotherapy, Cancer Immunol. Res., 10, 1042, 10.1158/2326-6066.CIR-22-0266 · DOI
  26. Wang, 2022, Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts, J. Hematol. Oncol., 15, 111, 10.1186/s13045-022-01325-0 · DOI
  27. Yan, 2022, Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity, J. Hematol. Oncol., 15, 104, 10.1186/s13045-022-01322-3 · DOI
  28. Nguyen, 2022, CAR T cell locomotion in solid tumor microenvironment, Cells, 11, 1974, 10.3390/cells11121974 · DOI
  29. Pandey, 2022, Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment, Adv. Drug Deliv. Rev., 188, 10.1016/j.addr.2022.114415 · DOI
  30. Ge, 2022, Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance, NPJ Precis.Oncol., 6, 31, 10.1038/s41698-022-00272-w · DOI
  31. Mittal, 2022, Radiotherapy-induced metabolic hallmarks in the tumor microenvironment, Trends Cancer, 8, 855, 10.1016/j.trecan.2022.05.005 · DOI
  32. Ferreira-Faria, 2022, Stem cell membrane-coated abiotic nanomaterials for biomedical applications, J. Control. Release, 351, 174, 10.1016/j.jconrel.2022.09.012 · DOI
  33. Zare, 2022, Encapsulation of miRNA and siRNA into nanomaterials for cancer therapeutics, Pharmaceutics, 14, 1620, 10.3390/pharmaceutics14081620 · DOI
  34. Rao, 2022, Development of nanomaterials to target articular cartilage for osteoarthritis therapy, Front. Mol. Biosci., 9, 10.3389/fmolb.2022.900344 · DOI
  35. Li, 2022, Hollow nanomaterials in advanced drug delivery systems: from single- to multiple shells, Adv. Mater.
  36. Caratelli, 2022, Nanomaterials and paper-based electrochemical devices: merging strategies for fostering sustainable detection of biomarkers, J. Mater. Chem. B, 10, 9021, 10.1039/D2TB00387B · DOI
  37. Uthaman, 2022, Nanomaterials for natural killer cell-based immunoimaging and immunotherapies in cancer, ACS Appl. Mater. Interfaces
  38. Kwon, 2022, Recent advances in chiral nanomaterials with unique electric and magnetic properties, Nano Convergence, 9, 32, 10.1186/s40580-022-00322-w · DOI
  39. Yu, 2022, Nanomaterials-based photosensitizers and delivery systems for photodynamic cancer therapy, Biomater.Adv., 135, 10.1016/j.bioadv.2022.212725 · DOI
  40. Zhu, 2022, Current progress in cancer treatment using nanomaterials, Front. Oncol., 12
  41. Rethi, 2022, Lipid-based nanomaterials for drug delivery systems in breast cancer therapy, Nanomaterials, 12, 2948, 10.3390/nano12172948 · DOI
  42. Kumar, 2022, Ligand conjugated lipid-based nanocarriers for cancer theranostics, Biotechnol. Bioeng., 119, 3022, 10.1002/bit.28205 · DOI
  43. Gao, 2022, Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy, Front. Chem., 10, 10.3389/fchem.2022.973666 · DOI
  44. Hua, 2021, Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review, Drug Deliv., 28, 1342, 10.1080/10717544.2021.1943056 · DOI
  45. Zhao, 2021, Poly(lactic-co-glycolic acid)-based composite bone-substitute materials, Bioact. Mater., 6, 346
  46. Swider, 2018, Customizing poly(lactic-co-glycolic acid) particles for biomedical applications, Acta Biomater., 73, 38, 10.1016/j.actbio.2018.04.006 · DOI
  47. Arif, 2022, Recent advances in 3D-printed polylactide and polycaprolactone-based biomaterials for tissue engineering applications, Int. J. Biol. Macromol., 218, 930, 10.1016/j.ijbiomac.2022.07.140 · DOI · Paper page
  48. Ilyas, 2022, Natural fiber-reinforced polycaprolactone green and hybrid biocomposites for various advanced applications, Polymers, 14, 182, 10.3390/polym14010182 · DOI
  49. Yang, 2021, The application of polycaprolactone in three-dimensional printing scaffolds for bone tissue engineering, Polymers, 13, 2754, 10.3390/polym13162754 · DOI
  50. Teoh, 2019, Three-dimensional printed polycaprolactone scaffolds for bone regeneration success and future perspective, Tissue Eng. A, 25, 931, 10.1089/ten.tea.2019.0102 · DOI
  51. Iranpour, 2016, Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens, J. Exp. Clin. Cancer Res., 35, 168, 10.1186/s13046-016-0444-6 · DOI
  52. Kohnepoushi, 2019, Poly lactic-co-glycolic acid nanoparticles containing human gastric tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy, Immunol. Investig., 48, 794, 10.1080/08820139.2019.1610889 · DOI
  53. Chen, 2020, Light-triggered OVA release based on CuS@poly(lactide-co-glycolide acid) nanoparticles for synergistic photothermal-immunotherapy of tumor, Pharmacol. Res., 158, 10.1016/j.phrs.2020.104902 · DOI
  54. Choi, 2020, Doxorubicin-loaded PLGA nanoparticles for cancer therapy: molecular weight effect of PLGA in doxorubicin release for controlling immunogenic cell death, Pharmaceutics, 12, 1165, 10.3390/pharmaceutics12121165 · DOI
  55. Dölen, 2021, PLGA nanoparticles co-encapsulating NY-ESO-1 peptides and IMM60 induce robust CD8 and CD4 T cell and B cell responses, Front. Immunol., 12, 10.3389/fimmu.2021.641703 · DOI
  56. Lin, 2021, Dual-functional PLGA nanoparticles co-loaded with indocyanine green and resiquimod for prostate cancer treatment, Int. J. Nanomedicine, 16, 2775, 10.2147/IJN.S301552 · DOI
  57. Koerner, 2021, PLGA-particle vaccine carrying TLR3/RIG-I ligand riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy, Nat. Commun., 12, 2935, 10.1038/s41467-021-23244-3 · DOI
  58. Garizo, 2021, p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer, J. Control. Release, 337, 329, 10.1016/j.jconrel.2021.07.035 · DOI
  59. Tang, 2022, In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4(+) and CD8(+) T-cell epitopes for cancer immunotherapy, Cancer Immunol. Immunother., 71, 2969, 10.1007/s00262-022-03209-1 · DOI
  60. Badiee, 2022, Glycogen kinase 3 inhibitor nanoformulation as an alternative strategy to inhibit PD-1 immune checkpoint, Int. J. Pharm., 622, 10.1016/j.ijpharm.2022.121845 · DOI
  61. Han, 2022, Nano co-delivery of plumbagin and dihydrotanshinone I reverses immunosuppressive TME of liver cancer, J. Control. Release, 348, 250, 10.1016/j.jconrel.2022.05.057 · DOI
  62. Lee, 2022, Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system, Biomaterials, 288, 10.1016/j.biomaterials.2022.121677 · DOI
  63. Kumar, 2015, IR 820 dye encapsulated in polycaprolactone glycol chitosan: poloxamer blend nanoparticles for photo immunotherapy for breast cancer, Mater. Sci. Eng. C Mater. Biol. Appl., 57, 321, 10.1016/j.msec.2015.08.006 · DOI
  64. Ding, 2008, Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy, Pharm. Res., 25, 2041, 10.1007/s11095-008-9594-3 · DOI
  65. van de Weert, 2000, Protein instability in poly(lactic-co-glycolic acid) microparticles, Pharm. Res., 17, 1159, 10.1023/A:1026498209874 · DOI
  66. Houchin, 2008, Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms, J. Pharm. Sci., 97, 2395, 10.1002/jps.21176 · DOI · Paper page
  67. Ling, 2022, Insights into the release mechanisms of antioxidants from nanoemulsion droplets, J. Food Sci. Technol., 59, 1677, 10.1007/s13197-021-05128-y · DOI
  68. Roy, 2022, Nanoemulsion-based dosage forms for the transdermal drug delivery applications: a review of recent advances, Expert Opin.Drug Deliv., 19, 303, 10.1080/17425247.2022.2045944 · DOI
  69. Garcia, 2022, Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils, Biomater. Sci., 10, 633, 10.1039/D1BM01537K · DOI
  70. Kupikowska-Stobba, 2021, Fabrication of nanoparticles for bone regeneration: new insight into applications of nanoemulsion technology, J. Mater. Chem. B, 9, 5221, 10.1039/D1TB00559F · DOI
  71. Ho, 2022, An overview of nanoemulsion characterization via atomic force microscopy, Crit. Rev. Food Sci. Nutr., 62, 4908, 10.1080/10408398.2021.1879727 · DOI
  72. Das, 2020, Application of nanoemulsion-based approaches for improving the quality and safety of muscle foods: a comprehensive review, Compr. Rev. Food Sci. Food Saf., 19, 2677, 10.1111/1541-4337.12604 · DOI
  73. Mustafa, 2020, Synthesis and technology of nanoemulsion-based pesticide formulation, Nanomaterials, 10, 1608, 10.3390/nano10081608 · DOI
  74. Zeng, 2018, Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy, J. Clin. Invest., 128, 1971, 10.1172/JCI96791 · DOI
  75. Kim, 2019, Lyophilizable and multifaceted toll-like receptor 7/8 agonist-loaded nanoemulsion for the reprogramming of tumor microenvironments and enhanced cancer immunotherapy, ACS Nano, 13, 12671, 10.1021/acsnano.9b04207 · DOI
  76. Zhang, 2020, Preparation of a new combination nanoemulsion-encapsulated MAGE1-MAGE3-MAGEn/HSP70 vaccine and study of its immunotherapeutic effect, Pathol. Res. Pract., 216, 10.1016/j.prp.2020.152954 · DOI
  77. Liu, 2020, Boosting natural killer cell-based cancer immunotherapy with selenocystine/transforming growth factor-beta inhibitor-encapsulated nanoemulsion, ACS Nano, 14, 11067, 10.1021/acsnano.9b10103 · DOI
  78. Jia, 2020, A pH-responsive Pickering nanoemulsion for specified spatial delivery of immune checkpoint inhibitor and chemotherapy agent to tumors, Theranostics, 10, 9956, 10.7150/thno.46089 · DOI
  79. Zhang, 2021, Biomimetic nanoemulsion for synergistic photodynamic-immunotherapy against hypoxic breast tumor, Angew. Chem. Int. Ed. Engl., 60, 10647, 10.1002/anie.202015590 · DOI
  80. Guo, 2022, Engineered nanomaterials for synergistic photo-immunotherapy, Biomaterials, 282, 10.1016/j.biomaterials.2022.121425 · DOI
  81. Tang, 2021, Multiple local therapeutics based on nano-hydrogel composites in breast cancer treatment, J. Mater. Chem. B, 9, 1521, 10.1039/D0TB02737E · DOI
  82. Ozkan, 2019, Nanocarriers used most in drug delivery and drug release: nanohydrogel, chitosan, graphene, and solid lipid, Turk.J.Pharm.Sci., 16, 481, 10.4274/tjps.galenos.2019.48751 · DOI
  83. Leber, 2017, Cationic nanohydrogel particles for therapeutic oligonucleotide delivery, Macromol. Biosci., 17, 10.1002/mabi.201700092 · DOI
  84. Jiang, 2019, Potent anti-tumor immunostimulatory biocompatible nanohydrogel made from DNA, Nanoscale Res. Lett., 14, 217, 10.1186/s11671-019-3032-9 · DOI
  85. Amin, 2022, Temperature-sensitive polymers to promote heat-triggered drug release from liposomes: towards bypassing EPR, Adv. Drug Deliv. Rev., 189, 10.1016/j.addr.2022.114503 · DOI
  86. De Leo, 2022, Liposomes containing nanoparticles: preparation and applications, Colloids Surf. B: Biointerfaces, 218, 10.1016/j.colsurfb.2022.112737 · DOI
  87. Satta, 2022, Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants, Theranostics, 12, 4779, 10.7150/thno.72339 · DOI
  88. Suhaimi, 2022, Application of liposomes in the treatment of infectious diseases, Life Sci., 305, 10.1016/j.lfs.2022.120734 · DOI
  89. Wang, 2022, Metal complex-based liposomes: applications and prospects in cancer diagnostics and therapeutics, J. Control. Release, 348, 1066, 10.1016/j.jconrel.2022.06.012 · DOI
  90. Yuan, 2022, Repetitive drug delivery using light-activated liposomes for potential antimicrobial therapies, Adv. Drug Deliv. Rev., 187, 10.1016/j.addr.2022.114395 · DOI
  91. Shen, 2020, Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer, Biomaterials, 255, 10.1016/j.biomaterials.2020.120190 · DOI
  92. Kateh Shamshiri, 2021, Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: in vitro and in vivo studies in a colon cancer mouse model, Life Sci., 264, 10.1016/j.lfs.2020.118605 · DOI
  93. Hu, 2021, Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy, ACS Nano, 15, 3123, 10.1021/acsnano.0c09681 · DOI
  94. Hashemzadeh, 2021, Recent advances in breast cancer immunotherapy: the promising impact of nanomedicines, Life Sci., 271, 10.1016/j.lfs.2021.119110 · DOI
  95. Su, 2021, Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy, J. Mater. Chem. B, 9, 3892, 10.1039/D1TB00256B · DOI
  96. Li, 2021, Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy, J. Control. Release, 335, 306, 10.1016/j.jconrel.2021.05.040 · DOI
  97. Cheng, 2021, Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy, Biomaterials, 275, 10.1016/j.biomaterials.2021.120964 · DOI
  98. Won, 2021, NIR irradiation-controlled drug release utilizing injectable hydrogels containing gold-labeled liposomes for the treatment of melanoma cancer, Acta Biomater., 136, 508, 10.1016/j.actbio.2021.09.062 · DOI
  99. Wang, 2022, CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment, Bioact. Mater., 17, 147
  100. Li, 2022, Spectral computed tomography with inorganic nanomaterials: state-of-the-art, Adv. Drug Deliv. Rev., 189, 10.1016/j.addr.2022.114524 · DOI
  101. Martano, 2022, Inorganic nanomaterials versus polymer-based nanoparticles for overcoming neurodegeneration, Nanomaterials, 12, 2337, 10.3390/nano12142337 · DOI
  102. Bianchi, 2022, Inorganic nanomaterials in tissue engineering, Pharmaceutics, 14, 6, 10.3390/pharmaceutics14061127 · DOI
  103. Djurišić, 2015, Toxicity of metal oxide nanoparticles: mechanisms, characterization, and avoiding experimental artefacts, Small, 11, 26, 10.1002/smll.201303947 · DOI
  104. Ding, 2018, Large-pore mesoporous-silica-coated upconversion nanoparticles as multifunctional immunoadjuvants with ultrahigh photosensitizer and antigen loading efficiency for improved cancer photodynamic immunotherapy, Adv. Mater., 30, 10.1002/adma.201802479 · DOI
  105. Liu, 2019, Polyethylenimine hybrid thin-shell hollow mesoporous silica nanoparticles as vaccine self-adjuvants for cancer immunotherapy, ACS Appl. Mater. Interfaces, 11, 47798, 10.1021/acsami.9b19446 · DOI
  106. Dong, 2020, Antigen-conjugated silica solid sphere as nanovaccine for cancer immunotherapy, Int. J. Nanomedicine, 15, 2685, 10.2147/IJN.S242463 · DOI
  107. Lee, 2020, Hollow mesoporous silica nanoparticles with extra-large mesopores for enhanced cancer vaccine, ACS Appl. Mater. Interfaces, 12, 34658, 10.1021/acsami.0c09484 · DOI
  108. Seth, 2020, Polydopamine-mesoporous silica core-shell nanoparticles for combined photothermal immunotherapy, ACS Appl. Mater. Interfaces, 12, 42499, 10.1021/acsami.0c10781 · DOI
  109. Chen, 2021, A size-tunable nanoplatform: enhanced MMP2-activated chemo-photodynamic immunotherapy based on biodegradable mesoporous silica nanoparticles, Biomater. Sci., 9, 917, 10.1039/D0BM01452D · DOI
  110. Chen, 2020, STING activator c-di-GMP-loaded mesoporous silica nanoparticles enhance immunotherapy against breast cancer, ACS Appl. Mater. Interfaces, 12, 56741, 10.1021/acsami.0c16728 · DOI
  111. Zhao, 2021, Cancer cell membrane camouflaged mesoporous silica nanoparticles combined with immune checkpoint blockade for regulating tumor microenvironment and enhancing antitumor therapy, Int. J. Nanomedicine, 16, 2107, 10.2147/IJN.S295565 · DOI
  112. Wang, 2022, Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site, Acta Biomater., 145, 235, 10.1016/j.actbio.2022.04.001 · DOI
  113. Zhang, 2018, Modified Fe(3)O(4) magnetic nanoparticle delivery of CpG inhibits tumor growth and spontaneous pulmonary metastases to enhance immunotherapy, Nanoscale Res. Lett., 13, 240, 10.1186/s11671-018-2661-8 · DOI
  114. Zhang, 2019, Intracellularly generated immunological gold nanoparticles for combinatorial photothermal therapy and immunotherapy against tumor, Nano Lett., 19, 6635, 10.1021/acs.nanolett.9b02903 · DOI
  115. Wang, 2019, PEGylated reduced-graphene oxide hybridized with Fe(3)O(4) nanoparticles for cancer photothermal-immunotherapy, J. Mater. Chem. B, 7, 7406, 10.1039/C9TB00630C · DOI
  116. Chen, 2020, Adoptive cellular immunotherapy of tumors via effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector, J. Mater. Chem. B, 8, 5052, 10.1039/D0TB00678E · DOI
  117. Janic, 2021, Therapeutic enhancement of radiation and immunomodulation by gold nanoparticles in triple negative breast cancer, Cancer Biol. Ther., 22, 124, 10.1080/15384047.2020.1861923 · DOI
  118. Chen, 2022, Effective CpG delivery using zwitterion-functionalized dendrimer-entrapped gold nanoparticles to promote T cell-mediated immunotherapy of cancer cells, Biosensors, 12, 71, 10.3390/bios12020071 · DOI
  119. Peterson, 2022, Recent advances and challenges in cancer immunotherapy, Cancers, 14, 3972, 10.3390/cancers14163972 · DOI
  120. Ma, 2022, Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy, Trends Immunol., 43, 833, 10.1016/j.it.2022.08.004 · DOI
  121. Yan, 2022, Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy, Acta Pharmacol. Sin., 43, 3045, 10.1038/s41401-022-00976-6 · DOI
  122. Ganapathy, 2022, CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?, Cancer Immunol. Immunother.
  123. Liu, 2022, Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy, Semin. Cancer Biol., 86, 259, 10.1016/j.semcancer.2022.06.004 · DOI
  124. Melo, 2022, Towards immunotherapy-induced normalization of the tumor microenvironment, Front. Cell Dev. Biol., 10, 10.3389/fcell.2022.908389 · DOI
  125. Raju, 2022, Nanoparticles mediated tumor microenvironment modulation: current advances and applications, J. Nanobiotechnol., 20, 274, 10.1186/s12951-022-01476-9 · DOI
  126. Rad, 2022, Understanding the tumor microenvironment in head and neck squamous cell carcinoma, Clin.Ttransl.Immunol., 11
  127. Huang, 2022, The role of indoleamine 2, 3-dioxygenase 1 in regulating tumor microenvironment, Cancers, 14, 2756, 10.3390/cancers14112756 · DOI
  128. Rostamizadeh, 2022, Recent advances in cancer immunotherapy: modulation of tumor microenvironment by toll-like receptor ligands, BioImpacts, 12, 261
  129. Zhang, 2022, Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment, Adv. Drug Deliv. Rev., 187, 10.1016/j.addr.2022.114365 · DOI
  130. Wang, 2022, Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment, J. Immunother. Cancer, 10, 10.1136/jitc-2021-004167 · DOI
  131. Aghanejad, 2022, A review on targeting tumor microenvironment: the main paradigm shift in the mAb-based immunotherapy of solid tumors, Int. J. Biol. Macromol., 207, 592, 10.1016/j.ijbiomac.2022.03.057 · DOI
  132. Kadkhoda, 2021, Advances in antibody nanoconjugates for diagnosis and therapy: a review of recent studies and trends, Int. J. Biol. Macromol., 185, 664, 10.1016/j.ijbiomac.2021.06.191 · DOI
  133. Chu, 2022, Crosstalk between pancreatic cancer cells and cancer-associated fibroblasts in the tumor microenvironment mediated by exosomal microRNAs, Int. J. Mol. Sci., 23, 9512, 10.3390/ijms23179512 · DOI
  134. Kamiya, 2022, The role of immune cells in the liver tumor microenvironment: an involvement of gut microbiota-derived factors, Int. Immunol., 34, 467, 10.1093/intimm/dxac020 · DOI
  135. Ritter, 2022, Adipose tissue-derived mesenchymal stromal/stem cells, obesity and the tumor microenvironment of breast cancer, Cancers, 14, 3908, 10.3390/cancers14163908 · DOI
  136. Xu, 2022, Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.
  137. Deng, 2022, Effects of Helicobacter pylori on tumor microenvironment and immunotherapy responses, Front. Immunol., 13, 10.3389/fimmu.2022.923477 · DOI
  138. Lu, 2022, Resident immune cells of the liver in the tumor microenvironment, Front. Oncol., 12
  139. Zhang, 2020, Self-assembled organic nanomaterials for drug delivery, bioimaging, and cancer therapy, ACS Biomater. Sci. Eng., 6, 4816, 10.1021/acsbiomaterials.0c00883 · DOI
  140. Zeng, 2021, The applications of functionalized DNA nanostructures in bioimaging and cancer therapy, Biomaterials, 268, 10.1016/j.biomaterials.2020.120560 · DOI
  141. Ghalkhani, 2022, Application of nanomaterials in development of electrochemical sensors and drug delivery systems for anticancer drugs and cancer biomarkers, Crit. Rev. Anal. Chem., 52, 481, 10.1080/10408347.2020.1808442 · DOI
  142. Kumar, 2022, N-acetyl-d-glucosamine decorated nano-lipid-based carriers as theranostics module for targeted anti-cancer drug delivery, Mater. Chem. Phys., 282, 10.1016/j.matchemphys.2022.125956 · DOI
  143. Yang, 2022, Cancer immunotherapy and delivery system: an update, Pharmaceutics, 14, 1630, 10.3390/pharmaceutics14081630 · DOI

Cited by

Sorted by citations

See all 61

Metadata

Authors
Kang, Y., & Li, S.
Venue
International Journal of Biological Macromolecules
Publisher
Elsevier BV
Published
2023-03
Volume
230
Pages
123159
ISSN
0141-8130
DOI
10.1016/j.ijbiomac.2023.123159
Cited by
61
References
2
Language
en
Licence
Funders
Fundamental Research Funds for the Central Universities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review